May 20, 2021


NCODA Welcomes New Executive Council Member 

Cazenovia, NY – NCODA, Inc. is pleased to announce the addition of a new Executive Council member. Dallas Lawry, DNP, FNP-C, OCN, Clinical Oncology Nurse III at UCLA Medical Center in Santa Monica Hospital, California was appointed to the Council in May 2021.

Dallas graduated from California State University Channel Islands with her BSN in 2014 and has worked at UCLA Medical Center in Santa Monica, California since then. During this time, she has spearheaded quality improvement projects that have been presented across the country, she has published an article on chemotherapy desensitization, and has lead groups of nurses overseas to volunteer in providing basic medical screenings to the Tibetan Buddhist refugee population in India. Dallas has received the Nurse Scientist of the Year (UCLA, 2018) and the Nightingale Award (Loyola University New Orleans) for her commitment to the profession of nursing. She recently graduated with her Doctor of Nursing Practice from Loyola University New Orleans (2021).

“NCODA has added another skilled and well-respected cancer care professional to our Executive Council,” said NCODA President Jim Schwartz, RPh. “Dallas is well positioned to help us continue executing on our Mission in 2021.” NCODA Founder and Executive Director Michael Reff, RPh, MBA noted, “Dallas brings a unique perspective to the Council, having served as an oncology nurse for several years. As NCODA grows, it is important that the organization has leaders with distinctive backgrounds and experiences so that we can continue to shape the cancer care landscape…and do it in a way that is Patient-Centered and Always Collaborative!”

For more information about NCODA’s Executive Council and general updates, visit



NCODA, Inc. is a 501(c)(3) organization. Our Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. For more information about NCODA’s Executive Council and general updates, visit www.ncod

Read More


STATEMENT FROM NCODA’s Legislative & Policy Advisory Committee
Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison
Phone: (919) 903-2057


The NCODA Legislative & Policy Advisory Committee wants to commend the Oklahoma Legislature and Governor Kevin Stitt for signing HB 2678 into law. Oklahoma HB 2678 was focused around Co-Pay Accumulators and would prohibit the use of CPA programs. NCODA has been at the forefront of this issue and speaking out against the use of CPA throughout the country and has been steadfast in the idea that these Co-Pay Accumulator programs eliminate the value of a drug manufacturer’s financial assistance to patients. This unfortunately increases the patient’s out of pocket cost and make it increasingly difficult for patients to access and receive the most affordable, high-level cancer care.

Our committee feels that it is necessary to celebrate the wins from around the country when states are able to focus on the needs of patients and pass bills into law that will shape the landscape and provide patients with the best possible chance to receive the care they deserve. NCODA’s focus is always patient-centric and we strongly believe that the state and federal governments should adopt the same mindset and focus on improving the lives of cancer patients from coast to coast. While battling cancer, patients should not have to worry about being able to afford the cost of their medications or potentially the lack of access to the preferred medication recommended by their physician. .

Oklahoma was not the only state to recently secure a major victory for patients, Alabama was able to follow suit and SB 227 was recently signed into law.  This law regulates Pharmacy Benefit Managers (PBMs) and will be going into effect on July 1st. Some of the major victories that were highlighted in the bill were:
1) Allowing a pharmacy to inform a patient about more affordable drug if one is available.

2) Prohibits the exclusive use of a mail-order pharmacy or a PBM affiliate pharmacy.
3) Requires a PBM to allow a pharmacy to participate in a network if the pharmacy agrees to the terms and conditions of the network contract, including reimbursements.
4) Allows a PBM to notify a patient that a less costly option for a specific prescription drug is available through a mail-order pharmacy or PBM affiliate, provided the notification states that switching to the less costly option is not mandatory.

NCODA is thrilled with these advancements and continues to focus on improving access to the best treatment options for patients. We hope that this positive trend will continue throughout the country and patients’ lives can be improved as barriers to affordable care are removed.

Read More

May 12, 2021

Texas Oncology’s leaders and physicians serve patients and their families in many ways – including those that lead them to the floor of the Texas State Capitol in Austin.

Recently, Steven R. Paulson, M.D., president and chairman of the board, Texas Oncology; Kathryn Hudson, M.D., hematologist and medical oncologist at Texas Oncology–Austin Central; and Jim Schwartz, executive director, pharmacy services, testified at the Texas Legislature on behalf of patients on several important state policies, including access to healthcare, the prior authorization process, and fertility preservation, among other topics affecting patients with cancer and those who care for or provide services for them. Read more.

Read More

The PAN Foundation is a national organization dedicated to helping federally and commercially insured people living with life-threatening, chronic, and rare diseases with the out-of-pocket costs for their prescribed medications. Learn more about certain patient assistance funds below.

Chronic Lymphocytic Leukemia

The PAN Foundation’s chronic lymphocytic leukemia (CLL) patient assistance fund provides a 12- month grant of $8,700 to pay for the deductibles, co-pays, and coinsurance costs associated with CLL treatment. The fund is currently open and applications are accepted on a rolling basis. Learn more about the fund today.

Philadelphia Chromosome Negative Myeloproliferative Neoplasms

The PAN Foundation’s Philadelphia chromosome negative myeloproliferative neoplasms (MPN) patient assistance fund provides a 12-month grant of $8,500 to pay for the deductibles, co-pays, and coinsurance costs associated with CLL treatment. The fund is currently open and applications are accepted on a rolling basis. Learn more about the fund today.

Waldenstrom Macroglobulinemia

The PAN Foundation’s Waldenstrom macroglobulinemia (WM) patient assistance fund provides a 12-month grant of $6,500 to pay for the deductibles, co-pays, and coinsurance costs associated with WM treatment. The fund is currently open and applications are accepted on a rolling basis. Learn more about the fund today.

Read More
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer

April 27, 2021

– Prescription Drug User Fee Act (PDUFA) Target Action Date Set for October 26, 2021

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s New Drug Application (NDA) for mobocertinib (TAK-788) for the treatment of adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC), as detected by an FDA-approved test, who have received prior platinum-based chemotherapy. Mobocertinib is the first oral therapy specifically designed to selectively target EGFR Exon20 insertion mutations.

“Patients with EGFR Exon20 insertion+ mNSCLC face considerable challenges, as current treatment options provide limited benefit, resulting in poor survival outcomes,” said Christopher Arendt, head, Oncology Therapeutic Area Unit, Takeda. “We are excited to be one step closer to offering mobocertinib as an effective oral therapy for NSCLC patients with EGFR Exon20 insertions that have received prior platinum-based chemotherapy and look forward to continuing conversations with regulatory agencies in the U.S. and around the globe.”

The NDA for mobocertinib is primarily based on results from the Phase 1/2 trial, which is evaluating the safety and efficacy of oral mobocertinib in patients with mNSCLC. The application was submitted under the FDA’s accelerated approval program. The review is being conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE), which provides a framework for concurrent submission and review of oncology products among international partners.

Takeda has established an Expanded Access Program (EAP) (NCT04535557) for patients in the U.S. who may be eligible to receive access to mobocertinib during the review of the NDA. Additional information about Takeda’s EAP is available here.

Learn more HERE

Read More